Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 13,066 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: Cancer Survivor, Prevention of Human Papillomavirus Infection
Interventions: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration, medical chart review; Biological · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 9 Years to 26 Years
Enrollment: 1,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 5
States / cities: Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 2 more

Conditions: Crohn Disease
Interventions: Etrolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 59
States / cities: Arcadia, California • La Jolla, California • Long Beach, California + 51 more

Conditions: Prostate Cancer
Interventions: tasquinimod, Placebo; Drug
Lead sponsor: Active Biotech AB; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 34
States / cities: Tucson, Arizona • Oxnard, California • Santa Monica, California + 31 more

Conditions: Diabetes
Interventions: FreeStyle Navigator II Continuous Glucose Monitoring System; Device
Lead sponsor: Abbott Diabetes Care; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Atlanta, Georgia • Santa Fe, New Mexico

Conditions: Chronic Pain
Interventions: Online CBT-CP based program, Virtual health coach-led CBT-CP based program; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 2,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Atlanta, Georgia • Duluth, Minnesota • Portland, Oregon + 1 more

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Gemcitabine, Oxaliplatin, Positron Emission Tomography, Rituximab; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Duarte, California • Newnan, Georgia • Zion, Illinois

Conditions: Acute Myelogenous Leukemia
Interventions: GRNVAC1; Biological
Lead sponsor: Asterias Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 6
States / cities: Atlanta, Georgia • Maywood, Illinois • St Louis, Missouri + 3 more

Conditions: Cardiovascular Disease
Interventions: Methotrexate, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 4,786 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 404
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 296 more

Conditions: Multiple Myeloma
Interventions: Etentamig, Lenalidomide, Daratumumab, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2042
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Facial Rhytidectomy (Face-lift)
Interventions: Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4); Biological
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 6
States / cities: Beverly Hills, California • Los Angeles, California • Atlanta, Georgia + 3 more

Conditions: Congestive Heart Failure (CHF)
Interventions: Telemedicine; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 30 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Gastroenteritis
Interventions: HIL-214; Biological
Lead sponsor: HilleVax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Rolling Hills Estates, California • Stockbridge, Georgia

Conditions: Critical Illness
Interventions: Parenteral Nutrition, Propofol, Clevidipine, Dextrose-containing IV Fluids, Enteral feeding; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Solid Tumor
Interventions: BDTX-189; Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 24
States / cities: Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more

Conditions: Hypersomnia, Idiopathic Hypersomnia, Narcolepsy
Interventions: Clarithromycin followed by placebo, Placebo then Clarithromycin; Drug
Lead sponsor: Lynn Marie Trotti; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Avelumab, Talazoparib, Talazoparib Tosylate; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 325
States / cities: Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more

Conditions: Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Interventions: Nerandomilast, Placebo matching nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 31
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 25 more

Conditions: Metabolic Acidosis
Interventions: TRC101, Placebo; Drug
Lead sponsor: Tricida, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 13
States / cities: Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 9 more

Conditions: Neuroblastoma
Interventions: filgrastim, sargramostim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, conventional surgery, neoadjuvant therapy; Biological · Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1988 – 2011
U.S. locations: 207
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Obinutuzumab, Chlorambucil; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 19
States / cities: Huntsville, Alabama • Rogers, Arkansas • La Jolla, California + 16 more

Conditions: Fibromyalgia
Interventions: [S,S]-Reboxetine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 101
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 87 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Glargine, LY2605541; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 66
States / cities: Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more

Conditions: Primary Biliary Cirrhosis
Interventions: Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 40
States / cities: Little Rock, Arkansas • Palo Alto, California • Pasadena, California + 32 more

Conditions: Herpes Simplex Virus
Interventions: Novel Antiviral Drug, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 98 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 15 more

Search by objective public record fields.

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Navigator II Continuous Glucose Monitor Home Use Study

Tailored Non-Pharmacotherapy Services for Chronic Pain

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

Cardiovascular Inflammation Reduction Trial

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures

CHF Management Using Telemedicine

Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

The Energy Dose Study

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Clarithromycin for the Treatment of Hypersomnia

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease

Combination Chemotherapy in Treating Children With Neuroblastoma

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia

A Study in Patients With Type 2 Diabetes Mellitus

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)